BioCardia, Inc.
BCDAAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Aug 24, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jun 9, 2026 |
| HC Wainwright & Co. | maintain | Buy | Sep 22, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 18, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 28, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 21, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 26, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 29, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 14, 2023 |
| HC Wainwright & Co. | maintain | Buy | Oct 11, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 6, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 10, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jul 24, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jun 21, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 11, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 30, 2023 |
| Dawson James | downgrade | Buy →Neutral | Nov 11, 2022 |
| HC Wainwright & Co. | maintain | Buy | Dec 20, 2021 |
| Dawson James | downgrade | Buy →Neutral | Apr 16, 2021 |
| Maxim Group | maintain | Buy | Nov 25, 2020 |
| Brookline Capital | maintain | Buy | Nov 25, 2020 |
| Alliance Global Partners | maintain | Buy | Nov 25, 2020 |
| Alliance Global Partners | maintain | Buy | Sep 21, 2020 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.15| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.13 | $-0.18 | — | — |
| May 15, 2026 | $-0.21 | $-0.17 | — | — |
| Mar 24, 2026 | $-0.06 | $-0.20 | — | $25.0K |
| Nov 12, 2025 | $-0.24 | $-0.25 | — | — |
| Aug 11, 2025 | $-0.40 | $-0.25 | — | — |
| May 14, 2025 | $-0.59 | $-0.39 | — | — |
| Mar 26, 2025 | $-0.25 | $-0.87 | $25.0K | $22.5K |
| Nov 13, 2024 | $-0.61 | $-1.19 | $58.0K | $20.0K |
News
SUNNYVALE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ: BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has completed the process with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) concerning the application materials required to obtain regulatory approval in Japan for its CardiAMP Cell Therapy System ("CardiAMP") for the treatment of ischemic heart failure.
SUNNYVALE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the FDA has accepted its pre-submission package for marketing clearance of its Helix catheter (“Helix”) intended for therapeutic and diagnostic agent delivery.
SUNNYVALE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the upcoming presentation of a scientific poster entitled “Cardiac Delivery of Autologous Minimally Processed Cell Therapy in HFrEF: Multicenter, Double Blind RCT (CardiAMP HF II)” at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 taking place in Phoeni…
SUNNYVALE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its revised Pre-Submission to FDA Center for Devices and Radiological Health (CDRH) under its Q-Submission program for the approval of its Helix Catheter (“Helix”) for therapeutic and diagnostic agent delivery to the heart.
SUNNYVALE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update on near term milestones.
SUNNYVALE, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that Peter Altman, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City, September 14-16, 2026.
SUNNYVALE, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces receipt of FDA confirmation of the outcome of its Pre-Submission Meeting on the Helix Transendocardial Delivery Catheter System (Helix).
BioCardia, Inc. (BCDA) Q2 2026 Earnings Call Transcript